DK3086870T3 - Plasmafereseanordning - Google Patents

Plasmafereseanordning Download PDF

Info

Publication number
DK3086870T3
DK3086870T3 DK14875719.8T DK14875719T DK3086870T3 DK 3086870 T3 DK3086870 T3 DK 3086870T3 DK 14875719 T DK14875719 T DK 14875719T DK 3086870 T3 DK3086870 T3 DK 3086870T3
Authority
DK
Denmark
Prior art keywords
plasma
separator
gal
blood
patient
Prior art date
Application number
DK14875719.8T
Other languages
English (en)
Inventor
Isaac Eliaz
Original Assignee
Eliaz Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/141,509 external-priority patent/US9549953B2/en
Application filed by Eliaz Therapeutics Inc filed Critical Eliaz Therapeutics Inc
Application granted granted Critical
Publication of DK3086870T3 publication Critical patent/DK3086870T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0445—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/09—Body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/005—Parameter used as control input for the apparatus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A61M2230/06—Heartbeat rate only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/30—Blood pressure

Claims (14)

1. Anordning til udførelse af plasmaferese, hvilken anordning omfatter: en første kanal (2000) til den pumpede bevægelse derigennem af blod tappet fra en pattedyrepatient; en separator (1012, 2012, 3012) i fluidforbindelse med den første kanal, hvilken separator er beregnet til separation af blodets cellekomponenter fra plasma; en søjleanordning (1008, 2008, 3008) i fluidforbindelse med separatoren og til strømning derigennem af plasmaet, hvor søjleanordningen er udformet til selektiv fjernelse af galectin-3 fra plasmaet for at tilvejebringe behandlet plasma; en anden kanal (2014) i fluidforbindelse med søjleanordningen og udformet til at modtage det behandlede plasma og kombinere det med blodlegemer separeret i separatoren før tilbageføring til patienten; hvor den første og den anden kanal tilvejebringer i alt væsentligt kontinuerlig strømning af blodet og plasmaet fra patienten og fører det tilbage til pattedyrepatienten; og kendetegnet ved, at anordningen omfatter mindst én supplerende søjleanordning (3008), udformet til fjernelse af en anden plasmakomponent end galectin-3.
2. Anordning ifølge krav 1, hvor anordningen omfatter mindst én åbning (3016), hvorigennem et terapeutisk middel kan tilsættes det behandlede plasma, separerede blod, eller begge, før tilbageføring til patienten.
3. Anordning ifølge krav 1, hvor anordningen endvidere omfatter en monitoreringsstation (3018) til at muliggøre monitorering og styring af plasmaferesen.
4. Anordning ifølge krav 3, hvor monitoreringsstationen (3018) tilvejebringer automatiseret styring af separatoren (3012) og søjleanordningen (3008), og endvidere tilvejebringer monitorering af patientindikatorer valgt fra gruppen bestående af pulsfrekvens, oxygenmætning, EKG-rytme og blodtryk.
5. Anordning ifølge krav 1, hvor separatoren (1012, 2012, 3012) omfatter en centrifugeseparator.
6. Anordning ifølge krav 5, hvor centrifugeseparatoren (1012, 2012, 3012) er en centrifugeseparator med kontinuerlig strømning.
7. Anordning ifølge krav 5, hvor separatoren (1012, 2012, 3012) er en diskontinuerlig strømningsseparator.
8. Anordning ifølge krav 1, hvor separatoren (1012, 2012, 3012) er en membranplasmaseparator.
9. Anordning ifølge krav 1, hvor anordningen endvidere omfatter mindst én pumpe (1006, 3006) til fremføring af de cellulære komponenter gennem kanalen.
10. Anordning ifølge krav 1, der endvidere omfatter mindst én åbning (3016), hvorigennem en blodkomponent valgt fra gruppen bestående af B-celler, T-celler, blodplader, stamceller og blandinger deraf kan høstes for modifikation og derefter føres tilbage til patienten via en kanal.
11. Anordning ifølge krav 1, hvor søjleanordningen (1008) omfatter et rør forsynet med et indre, hvor det indre bærer en sammensætning, der bærer et middel, der vil binde galectin-3, og hvor midlet befinder sig på et område af røret, gennem hvilket område plasmaet vil passere under anvendelse af anordningen.
12. Anordning ifølge krav 11, hvor midlet omfatter en ligand til binding af galectin-3.
13. Anordning ifølge krav 1, hvor anordningen omfatter en søjleanordning (3008), der fjerner tumornekrosefaktor a, og en søjleanordning (3008), der fjerner transformerende vækstfaktor β.
14. Anordning ifølge krav 9, hvor anordningen omfatter en åbning (1004, 3004) på opstrømssiden af separatoren til tilsætningen af et antikoagulans.
DK14875719.8T 2013-12-27 2014-05-20 Plasmafereseanordning DK3086870T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/141,509 US9549953B2 (en) 2011-12-08 2013-12-27 Galectin-3 plasmapheresis therapy
PCT/US2014/038694 WO2015099826A1 (en) 2013-12-27 2014-05-20 Plasmapheresis device

Publications (1)

Publication Number Publication Date
DK3086870T3 true DK3086870T3 (da) 2019-03-18

Family

ID=53479471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14875719.8T DK3086870T3 (da) 2013-12-27 2014-05-20 Plasmafereseanordning

Country Status (18)

Country Link
US (2) US10953148B2 (da)
EP (1) EP3086870B1 (da)
JP (1) JP6450767B2 (da)
KR (1) KR20160102440A (da)
CN (2) CN112691252A (da)
AU (1) AU2014370393B2 (da)
BR (1) BR112016013876B1 (da)
CA (1) CA2932902C (da)
DK (1) DK3086870T3 (da)
ES (1) ES2713388T3 (da)
IL (1) IL246086B (da)
MX (1) MX369551B (da)
MY (1) MY184230A (da)
NZ (1) NZ720820A (da)
RU (1) RU2680677C2 (da)
SG (2) SG11201604881TA (da)
WO (1) WO2015099826A1 (da)
ZA (1) ZA201604453B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509994A (ja) * 2015-03-27 2018-04-12 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 患者選択的アフェレシス
CA3029970A1 (en) * 2015-07-07 2017-01-12 Nashwa KHALIL Autoimmune mechanical immunomodulation
US10245285B2 (en) * 2016-04-28 2019-04-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
KR101844513B1 (ko) 2016-08-11 2018-04-02 삼성전자주식회사 단층 영상 처리 장치 및 단층 영상 처리 방법
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
US20200406230A1 (en) * 2018-03-08 2020-12-31 Glycorex Transplantation Ab A protein-binding product, a device containing said protein-binding product and a method for extracorporeal reduction of the level of protein in blood plasma
WO2019195414A1 (en) * 2018-04-03 2019-10-10 Fenwal, Inc. Plasmapheresis methods
EP3607978A1 (de) * 2018-08-06 2020-02-12 Pentracor GmbH Vereinfachte regeneration von apheresesäulen
US20200360426A1 (en) * 2019-05-16 2020-11-19 Isaac Eliaz Protocol and composition for suppression of allergic responses
KR20210043207A (ko) * 2019-10-11 2021-04-21 주식회사 싸이토딕스 비편향적 순환종양세포 연속 분리 장치 및 방법
CN113559344A (zh) * 2021-08-16 2021-10-29 赛若麦得（上海）生物技术有限公司 低容量血浆置换设备
ES2940917B2 (es) * 2023-02-22 2023-11-30 Tecnic Biotech S L Un filtro de aféresis y un método para la eliminación de platino residual en sangre

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625212A (en) 1969-07-09 1971-12-07 North American Biolog Inc Eliminating mistakes in plasmapheresis
US4464167A (en) * 1981-09-03 1984-08-07 Haemonetics Corporation Pheresis apparatus
US4531932A (en) * 1981-11-27 1985-07-30 Dideco S.P.A. Centrifugal plasmapheresis device
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
DE3926539A1 (de) * 1989-08-11 1991-02-14 Braun Melsungen Ag Verwendung von tentakel-kationenaustauschern zur selektiven eliminierung von low-density-lipoproteinen (ldl), fibrinogen und/oder harnstoff aus fluessigkeiten
US5348533A (en) * 1992-08-27 1994-09-20 Haemoentics Corporation Pheresis apparatus
US6245038B1 (en) 1997-01-07 2001-06-12 Helmut Borberg Method for treatment of ophthalmological diseases
US6061590A (en) * 1997-06-03 2000-05-09 Transonic Systems, Inc. Method and apparatus for predicting intradialytic morbid events through the monitoring of a central blood volume
US6627151B1 (en) 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US6274566B1 (en) 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
US6462029B1 (en) 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
AU766427B2 (en) * 1999-04-30 2003-10-16 Children's Hospital Medical Center Hemofiltration system and method baded on monitored patient parameters, supervisory control of hemofiltration, and adaptive control of pumps for hemofiltration
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
KR100978169B1 (ko) * 2002-05-30 2010-08-25 도레이 카부시키가이샤 면역 억제 물질 흡착재, 체외 순환 컬럼 및 암의 치료방법
WO2004014315A2 (en) 2002-08-13 2004-02-19 Arbios Systems, Inc. Selective plasma exchange therapy
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
WO2005077299A1 (en) * 2004-02-18 2005-08-25 Plasma Ventures Pty Ltd Isolated plasma and method for hyperimmunisation and plasma collection
CA2564859C (en) * 2004-04-27 2013-04-09 Vital Therapies, Inc. Metabolic detoxification system and method
JP2008511340A (ja) * 2004-04-30 2008-04-17 バイオフェレシス テクノロジーズ， インコーポレイテッド 患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
US8426567B2 (en) 2005-08-26 2013-04-23 Econugenics, Inc. Method for enhancing mammalian immunological function
DE102005061715A1 (de) * 2005-12-22 2007-06-28 Biobarries Gmbh Prozess zur Entfernung von C-reactivem Protein aus biologischen Flüssigkeiten durch Apherese
PL1875957T3 (pl) * 2006-07-07 2010-09-30 Gambro Lundia Ab Membrana do oddzielania osocza
JP2010131033A (ja) * 2007-03-16 2010-06-17 Medical Science Co Ltd 医療用吸着剤
DE102009037015A1 (de) * 2009-08-07 2011-02-17 Michael Hajek Vorrichtung und Verfahren zur Eliminierung von bioschädlichen Stoffen aus Körperflüssigkeiten
CA2777007C (en) * 2009-10-08 2019-08-20 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
WO2011112873A2 (en) * 2010-03-10 2011-09-15 Paul Tebbey Extracorporeal immunoadsorption treatment
EP3248946B1 (en) * 2010-05-14 2021-02-24 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
WO2012163544A1 (en) * 2011-06-01 2012-12-06 Biopheresis Technologies, Inc. Removal of soluble tumor necrosis factor receptor 2 (stnfr2)
US9549953B2 (en) 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
JP6276701B2 (ja) * 2011-12-08 2018-02-07 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 血漿交換療法によるガレクチン−３レベルの低減
ES2725573T3 (es) * 2012-05-14 2019-09-24 Childrens Medical Center Sistema para la modificación extracorpórea de sangre

Also Published As

Publication number Publication date
CN105828900A (zh) 2016-08-03
MX2016008420A (es) 2016-10-12
RU2016130573A (ru) 2018-02-01
JP6450767B2 (ja) 2019-01-09
IL246086A0 (en) 2016-07-31
EP3086870A4 (en) 2017-02-15
NZ720820A (en) 2019-10-25
CA2932902C (en) 2020-04-21
MX369551B (es) 2019-11-12
SG10201804910UA (en) 2018-07-30
ZA201604453B (en) 2017-09-27
US10953148B2 (en) 2021-03-23
RU2016130573A3 (da) 2018-03-23
CN112691252A (zh) 2021-04-23
US20160317734A1 (en) 2016-11-03
AU2014370393B2 (en) 2018-09-20
IL246086B (en) 2021-04-29
US20210138143A1 (en) 2021-05-13
BR112016013876A2 (da) 2017-09-19
RU2680677C2 (ru) 2019-02-25
CA2932902A1 (en) 2015-07-02
ES2713388T3 (es) 2019-05-21
EP3086870A1 (en) 2016-11-02
BR112016013876B1 (pt) 2022-03-22
AU2014370393A1 (en) 2016-06-23
JP2017507683A (ja) 2017-03-23
KR20160102440A (ko) 2016-08-30
SG11201604881TA (en) 2016-08-30
MY184230A (en) 2021-03-29
EP3086870B1 (en) 2019-01-02
WO2015099826A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
US20210138143A1 (en) Plasmapheresis device
US11389478B2 (en) Galectin-3 plasmapheresis therapy
Borberg 26 years of LDL–apheresis: a review of experience
Kohgo et al. Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial
Parés et al. Extracorporeal liver support in severe alcoholic hepatitis
AU2016262697B2 (en) Galectin-3 plasmapheresis therapy
CA3230785A1 (en) Apheresis of whole blood
Sivgin Apheresis Methods in Hyperlipidemias
CN116568345A (zh) 增加红细胞计数的技术
Pták Changes of selected hematologic parameters during long-term immunoadsorption therapy
WO2019053031A1 (en) PURIFIED BLOOD FOR USE IN ANTICANCER THERAPY